Invest in Africa’s Biologicals Platform
The Investment Opportunity
Invest in the Platform
AgriViro represents a rare convergence of proven science, operational infrastructure, and first-mover positioning in Africa’s rapidly expanding agricultural biologicals market.
The investment case is concrete: R&D is complete, production infrastructure is operational, the biologicals portfolio is in final regulatory approval, and commercial market entry is imminent. This is not seed-stage funding for a concept — it is growth capital for a platform ready to commercialise.
Global demand for biologicals and biorationals is accelerating, driven by regulatory restriction of synthetic chemistries, resistance pressure, and consumer demand for sustainable food. Africa is the next major frontier — and AgriViro is positioned as the primary infrastructure node for that transition.
Platform Partnerships
AgriViro’s production platform supports partnered, licensed, and contract biologicals programmes — giving multinational AgBio companies and regional players access to industrial-scale biologicals production in Africa without the capital cost of building their own infrastructure.
For detailed partnership models — licensing, co-development, contract production, and regional distribution — see our Partner With Us page.
Our partners
AgriViro’s infrastructure development and biologicals pipeline have been supported by the Technology Innovation Agency (TIA), an entity of South Africa’s Department of Science, Technology and Innovation (DSTI), providing government-backed validation of AgriViro’s scientific platform and its role as a strategic asset in the South African AgBio sector.
